Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
12
07
2021
accepted:
05
01
2022
revised:
04
11
2021
pubmed:
18
2
2022
medline:
26
5
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Alzheimer's disease (AD) biomarkers represent several neurodegenerative processes, such as synaptic dysfunction, neuronal inflammation and injury, as well as amyloid pathology. We performed an exome-wide rare variant analysis of six AD biomarkers (β-amyloid, total/phosphorylated tau, NfL, YKL-40, and Neurogranin) to discover genes associated with these markers. Genetic and biomarker information was available for 480 participants from two studies: EMIF-AD and ADNI. We applied a principal component (PC) analysis to derive biomarkers combinations, which represent statistically independent biological processes. We then tested whether rare variants in 9576 protein-coding genes associate with these PCs using a Meta-SKAT test. We also tested whether the PCs are intermediary to gene effects on AD symptoms with a SMUT test. One PC loaded on NfL and YKL-40, indicators of neuronal injury and inflammation. Four genes were associated with this PC: IFFO1, DTNB, NLRC3, and SLC22A10. Mediation tests suggest, that these genes also affect dementia symptoms via inflammation/injury. We also observed an association between a PC loading on Neurogranin, a marker for synaptic functioning, with GABBR2 and CASZ1, but no mediation effects. The results suggest that rare variants in IFFO1, DTNB, NLRC3, and SLC22A10 heighten susceptibility to neuronal injury and inflammation, potentially by altering cytoskeleton structure and immune activity disinhibition, resulting in an elevated dementia risk. GABBR2 and CASZ1 were associated with synaptic functioning, but mediation analyses suggest that the effect of these two genes on synaptic functioning is not consequential for AD development.
Identifiants
pubmed: 35173266
doi: 10.1038/s41380-022-01437-6
pii: 10.1038/s41380-022-01437-6
pmc: PMC9126805
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
CASZ1 protein, human
0
Chitinase-3-Like Protein 1
0
DNA-Binding Proteins
0
Intercellular Signaling Peptides and Proteins
0
NLRC3 protein, human
0
Transcription Factors
0
tau Proteins
0
Neurogranin
132654-77-4
Dithionitrobenzoic Acid
9BZQ3U62JX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1990-1999Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : CIHR
Pays : Canada
Investigateurs
Alexander Neumann
(A)
Fahri Küçükali
(F)
Isabelle Bos
(I)
Stephanie J B Vos
(SJB)
Sebastiaan Engelborghs
(S)
Ellen De Roeck
(E)
Magda Tsolaki
(M)
Frans Verhey
(F)
Pablo Martinez-Lage
(P)
Mikel Tainta
(M)
Giovanni Frisoni
(G)
Oliver Blin
(O)
Jill Richardson
(J)
Régis Bordet
(R)
Philip Scheltens
(P)
Julius Popp
(J)
Gwendoline Peyratout
(G)
Peter Johannsen
(P)
Lutz Frölich
(L)
Rik Vandenberghe
(R)
Yvonne Freund-Levi
(Y)
Johannes Streffer
(J)
Simon Lovestone
(S)
Cristina Legido-Quigley
(C)
Mara Ten Kate
(M)
Frederik Barkhof
(F)
Henrik Zetterberg
(H)
Lars Bertram
(L)
Pieter Jelle Visser
(PJ)
Christine van Broeckhoven
(C)
Kristel Sleegers
(K)
Informations de copyright
© 2022. The Author(s).
Références
Polderman TJC, Benyamin B, de Leeuw CA, Sullivan PF, van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat Genet. 2015;47:702–9.
pubmed: 25985137
doi: 10.1038/ng.3285
Zhang Q, Sidorenko J, Couvy-Duchesne B, Marioni RE, Wright MJ, Goate AM, et al. Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture. Nat Commun. 2020;11:1–11.
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27.
pubmed: 23150934
doi: 10.1056/NEJMoa1211851
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16.
pubmed: 23150908
doi: 10.1056/NEJMoa1211103
De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathol. 2019;138:201–20.
pubmed: 30903345
pmcid: 6660495
doi: 10.1007/s00401-019-01994-1
Grozeva D, Saad S, Menzies GE, Sims R. Benefits and challenges of rare genetic variation in Alzheimer’s disease. Curr Genet Med Rep. 2019;7:53–62.
doi: 10.1007/s40142-019-0161-5
Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer’s disease. Nat Neurosci. 2020;23:311–22.
pubmed: 32112059
doi: 10.1038/s41593-020-0599-5
Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer’s fluid biomarkers. 136. Springer Berlin Heidelberg; 2018.
Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284:643–63.
pubmed: 30051512
doi: 10.1111/joim.12816
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67.
pubmed: 23477989
doi: 10.1016/S1474-4422(13)70044-9
Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673–84.
pubmed: 27068280
doi: 10.1016/S1474-4422(16)00070-3
Jin M, Cao L, Dai YP. Role of neurofilament light chain as a potential biomarker for Alzheimer’s disease: a correlative meta-analysis. Front Aging Neurosci. 2019;11:1–10.
doi: 10.3389/fnagi.2019.00254
Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12:1–21.
doi: 10.1186/s13024-017-0226-4
Mavroudis IA, Petridis F, Chatzikonstantinou S, Kazis D. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer’s disease and mild cognitive impairment. Aging Clin Exp Res. 2020;32:1639–46.
pubmed: 31463927
doi: 10.1007/s40520-019-01326-z
Hong S, Prokopenko D, Dobricic V, Kilpert F, Bos I, Vos SJB, et al. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD multimodal biomarker discovery dataset. Transl Psychiatry. 2020. 2020. https://doi.org/10.1101/774554 .
Hong S, Dobricic V, Ohlei O, Bos I, Vos SJB, Prokopenko D, et al. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels. Alzheimer’s Dement. 2021. 2021. https://doi.org/10.1002/alz.12330 .
Simino J, Wang Z, Bressler J, Chouraki V, Yang Q, Younkin SG, et al. Whole-exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the atherosclerosis risk in communities—neurocognitive study. PLoS ONE. 2017;12:e0180046.
pubmed: 28704393
pmcid: 5509141
doi: 10.1371/journal.pone.0180046
Aschard H, Vilhjálmsson BJ, Greliche N, Morange PE, Trégouët DA, Kraft P. Maximizing the power of principal-component analysis of correlated phenotypes in genome-wide association studies. Am J Hum Genet. 2014;94:662–76.
pubmed: 24746957
pmcid: 4067564
doi: 10.1016/j.ajhg.2014.03.016
Galesloot TE, van Steen K, Kiemeney LALM, Janss LL, Vermeulen SH. A comparison of multivariate genome-wide association methods. PLoS One. 2014;9:e95923
pubmed: 24763738
pmcid: 3999149
doi: 10.1371/journal.pone.0095923
Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The EMIF-AD multimodal biomarker discovery study: design, methods and cohort characteristics. Alzheimer’s Res Ther. 2018;10:1–9.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–13.
pubmed: 19296504
pmcid: 2696350
doi: 10.1002/ana.21610
Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, et al. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry. 2013;18:781–7.
pubmed: 23608917
pmcid: 3777294
doi: 10.1038/mp.2013.24
Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimer’s Dement. 2019;15:644–54.
doi: 10.1016/j.jalz.2019.01.004
Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, et al. Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.
pubmed: 31836810
pmcid: 6911086
doi: 10.1038/s41598-019-54204-z
Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93:E252–E260.
pubmed: 31182505
pmcid: 6656645
doi: 10.1212/WNL.0000000000007767
Wang L. Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease. Aging Clin Exp Res. 2019;31:185–91.
pubmed: 29667155
doi: 10.1007/s40520-018-0948-3
Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF. Proteom Clin Appl. 2015;9:715–31.
doi: 10.1002/prca.201400178
Folstein ME. A practical method for grading the cognitive state of patients for the children. J Psychiatr Res. 1975;12:189–98.
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Auer PL, Reiner AP, Leal SM. The effect of phenotypic outliers and non-normality on rare-variant association testing. Eur J Hum Genet. 2016;24:1188–94.
pubmed: 26733287
pmcid: 4970685
doi: 10.1038/ejhg.2015.270
Josse J, Husson F. missMDA: a package for handling missing values in multivariate data analysis. J Stat Softw. 2016;70:1–31.
doi: 10.18637/jss.v070.i01
Revelle W. psych: procedures for psychological, psychometric, and personality research. Northwest University, Evanston, Illinois. 2014;165.
R Core Team. R: a language and environment for statistical computing. 2017.
Lee S, Wu MC, Lin X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics. 2012;13:762–75.
pubmed: 22699862
pmcid: 3440237
doi: 10.1093/biostatistics/kxs014
Lee S, Teslovich TM, Boehnke M, Lin X. General framework for meta-analysis of rare variants in sequencing association studies. Am J Hum Genet. 2013;93:42–53.
pubmed: 23768515
pmcid: 3710762
doi: 10.1016/j.ajhg.2013.05.010
Day FR, Loh PR, Scott RA, Ong KK, Perry JRB. A robust example of collider bias in a genetic association study. Am J Hum Genet. 2016;98:392–3.
pubmed: 26849114
pmcid: 4746366
doi: 10.1016/j.ajhg.2015.12.019
Philipps V, Amieva H, Andrieu S, Dufouil C, Berr C, Dartigues J-F, et al. Normalized mini-mental state examination for assessing cognitive change in population-based brain aging studies. Neuroepidemiology. 2014;43:15–25.
pubmed: 25248074
doi: 10.1159/000365637
Zhong W, Spracklen CN, Mohlke KL, Zheng X, Fine J, Li Y. Multi-SNP mediation intersection-union test. Bioinformatics. 2019;35:4724–9.
pubmed: 31099385
pmcid: 6853702
doi: 10.1093/bioinformatics/btz285
Li W, Bai X, Li J, Zhao Y, Liu J, Zhao H, et al. The nucleoskeleton protein IFFO1 immobilizes broken DNA and suppresses chromosome translocation during tumorigenesis. Nat Cell Biol. 2019;21:1273–85.
pubmed: 31548606
doi: 10.1038/s41556-019-0388-0
Ganote CE, Armstrong SC. Dystrophin-associated protein complex and heart failure. Lancet. 2002;359:905–6.
pubmed: 11918903
doi: 10.1016/S0140-6736(02)08013-3
Prokopenko D, Lee S, Hecker J, Mullin K, Morgan S, Katsumata Y, et al. Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimer’s disease-associated genes: DTNB and DLG2. MedRxiv. 2021:2021.06.09.21258576. (in this issue).
Eren E, Özören N. The NLRP3 inflammasome: a new player in neurological diseases. Turk J Biol. 2019;43:349–59.
pubmed: 31892810
pmcid: 6911260
doi: 10.3906/biy-1909-31
Zha L, Yu Z, Fang J, Zhou L, Guo W, Zhou J. NLRC3 delays the progression of AD in APP/PS1 mice via inhibiting PI3K activation. Oxid Med Cell Longev. 2020;2020:5328031.
pubmed: 33425209
pmcid: 7775163
doi: 10.1155/2020/5328031
Schirmer L, Velmeshev D, Holmqvist S, Kaufmann M, Werneburg S, Jung D, et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature. 2019;573:75–82.
pubmed: 31316211
pmcid: 6731122
doi: 10.1038/s41586-019-1404-z
Schaller L, Lauschke VM. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum Genet. 2019;138:1359–77.
pubmed: 31679053
pmcid: 6874521
doi: 10.1007/s00439-019-02081-x
Agora. https://agora.ampadportal.org/genes/ (genes-router:gene-details/ENSG00000184999). Accessed 21 Oct 2021.
Govindpani K, Turner C, Waldvogel HJ, Faull RLM, Kwakowsky A. Impaired expression of GABA signaling components in the Alzheimer’s disease middle temporal gyrus. Int J Mol Sci. 2020;21:14–17.
doi: 10.3390/ijms21228704
Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Hidaka S, Abrahamson EE, et al. Changes in hippocampal GABABR1 subunit expression in Alzheimer’s patients: association with Braak staging. Acta Neuropathol. 2005;109:467–74.
pubmed: 15759131
doi: 10.1007/s00401-005-0985-9
Huang RT, Xue S, Wang J, Gu JY, Xu JH, Li YJ, et al. CASZ1 loss-of-function mutation associated with congenital heart disease. Gene. 2016;595:62–68.
pubmed: 27693370
doi: 10.1016/j.gene.2016.09.044
Qiu X-B, Qu X-K, Li R-G, Liu H, Xu Y-J, Zhang M, et al. CASZ1 loss-of-function mutation contributes to familial dilated cardiomyopathy. Clin Chem Lab Med. 2017;55:1417–25.
pubmed: 28099117
doi: 10.1515/cclm-2016-0612
Bettens K, Brouwers N, Engelborghs S, Lambert J-C, Rogaeva E, Vandenberghe R, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener. 2012;7:3.
pubmed: 22248099
pmcid: 3296573
doi: 10.1186/1750-1326-7-3
Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer’s disease: mechanisms, genetics, and lessons from other pathologies. Front Neurosci. 2019;13:1–27.
doi: 10.3389/fnins.2019.00164